We strongly recommend our NAD+ IV Trio for reducing the risk of Alzheimer’s disease (AD). The NAD+ IV Trio includes an NAD+ IV, Myer’s Cocktail IV, and glutathione IV, all of which work together to improve cellular issues characteristic of AD. NAD+ levels are known to decrease with age, and its deficiency is implicated in various neurodegenerative disorders including AD(17). Interest in NAD+ as a potential treatment for AD continues to grow due to NAD+‘s ability to reduce Aβ plaques, improve mitochondrial dysfunction, and reduce brain cell death(18-20).
In addition to NAD+, the Myer’s IV has strong antioxidant effects that may reduce risk of AD by decreasing oxidative stress and neuroinflammation(21-22). Levels of magnesium, which is also in the Myer’s IV, are low in many people with AD and may contribute to AD progression and cognitive decline(23).
Last, but not least, increasing glutathione levels may improve cognitive function and reduce risk of AD(24-26). Glutathione is considered the “master antioxidant”, but its levels are low in the brains of people with AD(24). Glutathione deficiency results in increased oxidative stress and associated cellular damage, so increasing its levels is vital to reducing risk of AD(26). Taken together, NAD+, the Myer’s IV, and glutathione target many root causes of AD as well as improve numerous cellular functions that are impaired in AD. Glutathione also has strong potential to decrease the oxidative stress heavily involved in AD.
Learn more about IV Therapy…